FDA labels AbbVie hep C drug Breakthrough

Share this article:

Abbvie and partner Enanta Pharmaceuticals have tucked a Breakthrough Therapy label under their belts. The FDA granted the expedited review status Friday to the experimental hepatitis C treatment that includes protease inhibitor ABT-450 and ombitasvir and dasabuvir, with or without the interferon ribavirin.

The all-oral's progress means the FDA will review the drug within six months, and that AbbVie deposited an additional milestone payment into Enanta's accounts.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA lifts OncoMed partial hold

The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.